SCHEMBL363528

SCHEMBL363528

Oc1ccccc1OC(F)F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.50
CA1 P00915 2/20 0.50
TP53 P04637 2/20 0.50
TSHR P16473 1/20 0.50
LMNA P02545 3/20 0.46
MAPT P10636 3/20 0.46
GAA P10253 2/20 0.46
JAK2 O60674 1/20 0.46
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
HTT P42858 1/20 0.42
DRD1 P21728 1/20 0.42
ALDH1A1 P00352 3/20 0.41
CA12 O43570 2/20 0.41
POLB P06746 2/20 0.41
KDM4E B2RXH2 2/20 0.41
CYP3A4 P08684 2/20 0.41
HPGD P15428 2/20 0.41
ALOX15 P16050 2/20 0.41
HSD17B10 Q99714 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10932877 0.82 CA2 (0.52) CA2CA1TP53TSHRLMNA
SCHEMBL29135349 0.82 CA2 (0.46) CA2CA1TP53TSHRLMNA
SCHEMBL4654255 0.82 DRD1 (0.48) CA2CA1MAPTGAAKMT2A
SCHEMBL11002071 0.79 GAA (0.45) CA2CA1TP53TSHRLMNA
SCHEMBL4790422 0.79 CA2 (0.43) CA2CA1TP53TSHRLMNA
SCHEMBL9427353 0.78 CA2 (0.52) CA2CA1TP53TSHRLMNA
SCHEMBL10417879 0.76 CA2 (0.50) CA2CA1TP53TSHRLMNA
SCHEMBL8747528 0.76 CA2 (0.56) CA2CA1TP53TSHRLMNA
SCHEMBL29737595 0.76 TP53 (0.56) CA2CA1TP53TSHRLMNA
SCHEMBL104203 0.76 TP53 (0.56) CA2CA1TP53TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1312107-C 3,4-difluoro-2-methoxy phenol ester derivative and its preparing method and use UNIV TSINGHUA (CN) 2007-04-25 CN claimed
CN-1709855-A 3,4-difluoro-2-methoxy phenol ester derivative and its preparing method and use UNIV TSINGHUA (CN) 2005-12-21 CN claimed
EP-0096263-B1 DIFLUOROMETHOXYPHENYLTHIOPHOSPHORIC-ACID ESTERS BASF Aktiengesellschaft (DE) 1985-12-11 EP claimed
US-20250346600-A1 TRICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2025-11-13 US disclosed
US-20250138419-A1 COATING MATERIAL FOR PHOTOLITHOGRAPHY, RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2025-05-01 US disclosed
WO-2025054488-A1 TRICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. (US) 2025-03-13 WO disclosed
EP-4498159-A1 COATING MATERIAL FOR PHOTOLITHOGRAPHY, RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2025-01-29 EP disclosed
CN-119335814-A Coating material for optical lithography, resist material, and pattern forming method 信越化学工业株式会社 2025-01-21 CN disclosed
US-11673864-B2 Pyridone amides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-06-13 US disclosed
EP-3865475-A1 PROCESS FOR PREPARING PYRIDONE AMIDES WHICH ARE MODULATORS OF SODIUM CHANNELS AND INTERMEDIATE COMPOUNDS USED THEREIN Vertex Pharmaceuticals Incorporated (US) 2021-08-18 EP disclosed
US-11053234-B2 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-07-06 US disclosed
CN-1011969-B Benzimidazole derivatives and their preparation BYK GULDEN LOMBERG CHEM FAB (DE) 1991-03-13 CN disclosed
EP-0166287-B1 DIALKOXYRIDINES, PROCESS FOR THEIR PREPARATION, THEIR APPLICATION AND MEDICAMENTS CONTAINING THEM Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1989-08-23 EP disclosed
US-4758579-A e.g. pantoprazole or pantoprazole sodium BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1988-07-19 US disclosed
US-4686230-A Picoline derivative useful as gastric acid secretion inhibitors BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1987-08-11 US disclosed
CN-85104684-A The dialkoxy pyridine, their preparation method, purposes and contain their medicine 1986-12-31 CN disclosed
EP-0166287-A1 Dialkoxyridines, process for their preparation, their application and medicaments containing them Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1986-01-02 EP disclosed
EP-0096263-B1 DIFLUOROMETHOXYPHENYLTHIOPHOSPHORIC-ACID ESTERS BASF Aktiengesellschaft (DE) 1985-12-11 EP disclosed
US-4512984-A Difluoromethoxyphenyl thiophosphates as pesticides BASF AKTIENGESELLSCHAFT (DE) 1985-04-23 US disclosed
EP-0134400-A2 Fluoroalkoxysubstituted pyridylmethylthio-(or sulfinyl-)benzimidazoles having a secretolytic activity Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1985-03-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11053234-B2 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors HPGDS, PTGDR, PTGER1 CA2 3198/4885CA1 4688/4885TP53 4495/4885
US-11673864-B2 Pyridone amides as modulators of sodium channels SCN5A, SCN1A, KCNJ2 CA2 311/4885CA1 2724/4885TP53 4792/4885
US-20250346600-A1 TRICYCLIC DERIVATIVES AND RELATED USES WRN, RECQL, BLM CA2 4248/4885CA1 4352/4885TP53 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.